生物等效性
最大值
加药
交叉研究
医学
药理学
胶囊
药代动力学
置信区间
缬沙坦
剂型
内科学
化学
色谱法
安慰剂
生物
替代医学
植物
病理
血压
作者
Romain Séchaud,Peter Gräf,Hilde Bigler,E Gruendl,Martin Letzkus,Michael Merz
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics
[Dustri-Verlag Dr. Karl Feistle]
日期:2002-01-01
卷期号:40 (01): 35-40
被引量:17
摘要
Two formulations of valsartan (Diovan), 320 mg tablets and marketed 160 mg capsules, were evaluated for bioequivalence after single dosing.The study was designed as a single-center, open-label, 2-treatment, 3-period, repeated-measure (replicated), randomized crossover comparison in 40 healthy volunteers, all of whom completed the study successfully. Valsartan was determined in plasma by HPLC with fluorescence detection after solid-phase extraction.Comparing the new 320 mg tablet with 2 x 160 mg of the marketed valsartan capsules taken at the same time, the ratios of the least square means for AUC(0-t), AUC(all), AUC(0-infinity) and Cmax were 1.11, 1.10, 1.10 and 1.09, respectively. The 90% confidence intervals of the AUC and Cmax parameters were within the range of 0.80-1.25.Bioequivalence of the new 320 mg tablet with 2 marketed 160 mg capsules was demonstrated.
科研通智能强力驱动
Strongly Powered by AbleSci AI